Return to search

In vitro saturační studie 99mTc-HYNIC-ramucirumabu na PC-3 buňkách / In vitro saturation study of 99mTc-HYNIC-ramucirumab on PC-3 cell line

v anglickom jazyku Charles University in Prague Faculty of Pharmacy in Hradec Králové Department of Biophysics and Physical Chemistry Student: František Lach Supervisor: Mgr. Pavel Bárta, PhD Consultant: Mgr. Lucie Hyršová Title of diploma thesis: In vitro saturation study of 99m Tc-HYNIC-ramucirumab on PC-3 cell line The number of malignant tumours in the population has increased in recent years. Due to the frequent serious sides effects of chemotherapeutic drugs on the whole organism, targeted antitumor therapy is at the forefront. Due to its specific effect on the regulatory and signal pathways of protein structures, monoclonal antibodies are used for the target anti-tumour therapy. The basic properties of the growing tumour include vasculogenesis (the ability to build new blood vessels from the endothelial precursors) and angiogenesis (the process of self-inducing formation of blood vessels). Endothelial tumour progenitors include vascular endothelial growth factor (VEGF). VEGF activates its biological activity by binding to its transmembrane tyrosine-kinase receptors VEGFR. Indeed, the inhibition of the vascular endothelial factor receptors is the target of some monoclonal antibodies. Ramucirumab is a monoclonal antibody that selectively inhibits VEGF receptor type 2 (VEGFR-2) and thereby...

Identiferoai:union.ndltd.org:nusl.cz/oai:invenio.nusl.cz:380751
Date January 2018
CreatorsLach, František
ContributorsBárta, Pavel, Hyršová, Lucie
Source SetsCzech ETDs
LanguageSlovak
Detected LanguageEnglish
Typeinfo:eu-repo/semantics/masterThesis
Rightsinfo:eu-repo/semantics/restrictedAccess

Page generated in 0.0013 seconds